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Introduction
Cervical cancer is the most common gynecologic malig-
nancy in Taiwan. The incidence of cervical cancer is
51.88/100,000 women in 20021. Over 99% of cervical
cancers are caused by the high-risk group of human
papillomavirus (HPV)2, which includes types 16 and 18
that are responsible for over 70% of cervical cancer.
Quadrivalent (Gardasil®; Merck & Co., NJ, USA) and 
bivalent (Cervarix®; GlaxoSmithKline, London, UK) HPV
vaccines are recently available treatments for preven-
tion of cervical infection of the two high-risk HPV
types before the onset of pre-cancer lesion (cervical
intraepithelial neoplasm [CIN]). Cervical cancer is also
a slowly progressing local disease, which occurs 5–30
years after the development of CIN lesions. CIN lesions
can be detected by Papanicolaou smear and treated
with local excision procedure or simple hysterectomy.
Unfortunately, if CIN lesions develop into invasive can-
cer, the treating modalities become more com-
plicated, and usually at a sacrifice to the quality of life
of these cervical cancer patients. We would like to
review the modern trends in the treatment of invasive
cervical cancer.
Trend 1: More Conservative Treatment in
Early Stage Disease
The early stage of cervical cancer is defined as FIGO
clinical stages IA1 to IIA, where the lesion is confined
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within the cervical portion to the upper vagina without
parametrial involvement. There are 3 main histologic
types of cervical cancer: squamous cell carcinoma (SCC),
adenocarcinoma, and adenosquamous cell carcinoma.
SCC offers a better prognosis and allows for more con-
servative modalities than the other two types. Stage IA1
SCC cervical cancer can be treated by conization with the
intention of preserving the uterus if fertility is desired,
because the possibility of pelvic lymph node metastases
is <1%3. Simple hysterectomy without pelvic lymph node
dissection is acceptable if fertility is no longer a concern.
On the other hand, the management of adenocarci-
noma and adenosquamous cell carcinoma remains as
conization followed by hysterectomy, for fear of a skip
lesion in the cervical portion.
The traditional treatment of stage IA2 cervical cancer
is class 2 radical hysterectomy (modified radical hysterec-
tomy) with pelvic lymph node dissection. Alternatively,
unlike adenocarcinoma or adenosquamous carcinoma,
radical trachelectomy with pelvic node dissection is
acceptable for SCC cervical cancer if fertility preservation
is desired, because the probability of a nodal metastasis
averages 7.3%4.
The conventional treatment of stage IB1 or IIA
tumors (4 cm or less in diameter) requires class III
Wertheim’s radical hysterectomy plus bilateral pelvic
lymph node dissection. Yang et al.5 suggested a more
conservative modality, which employed class II radical
hysterectomy (modified radical hysterectomy) and
yielded results comparable to the traditional surgical
method with low voiding or defecation dysfunction.
The local failure rate was not increased and the com-
plication rate was decreased if postoperative radio-
therapy was required. The local recurrence in one
adenocarcinoma patient revealed that conservative
modalities were unsuitable for histologic types other
than SCC.
Patients with stage IB2 or IIA tumors (4 cm or more
in diameter) were favorably treated with concurrent
chemoradiation therapy (CCRT) than those receiving
large-scale surgeries6,7. There was a 30–40% possibility of
pelvic lymph node metastases, and postoperative radio-
therapy was eventually unavoidable. The morbidity of
surgery plus CCRT was higher than surgery or CCRT alone.
The quality of life became worse in the combination
group. It has been suggested that pelvic lymph node
dissection will not increase the complication during con-
secutive CCRT and that the excision of existing bulky
nodes is beneficial.
Trend 2: CCRT
Ever since 1988, CCRT has replaced the traditional radio-
therapy and become the standard primary treatment
of locally advanced cervical cancer (stages IIB–IVA). When
a combination of cisplatin and 5-fluorouracil (5-FU)
was used as radiosensitizers during pelvic radiation and
brachytherapy, the local control rate, progressive-free
survival, and overall survival were improved. Although
the cisplatin–5-FU combination incurred other treat-
ment morbidities such as severe bone marrow suppres-
sion, this morbidity had been shown to be acceptable
in a recent literature8.
CCRT was also shown to be applicable in early-
stage cervical cancer patients who were not suitable
for radical surgery or had major risk factors after radical
surgery. The schedule of chemotherapy during radio-
therapy is cisplatin plus 5-FU for three courses with 
a 21-day interval between the courses, or a single-
agent cisplatin (40 mg/m2) given weekly for six courses.
Ikushima et al.9 reported that the reduction of the
weekly cisplatin dose to 30 mg/m2 significantly reduced
hematologic toxicity. A new chemotherapeutic sched-
ule of daily cisplatin (20 mg/m2/d for 5 consecutive
days) for a total of two courses during radiotherapy has
been developed, and it was reported to have a better
outcome10. Other chemotherapeutic agents, such as
gemcitabine, oxaliplatin, etoposide, liposomal doxoru-
bicin, carboplatin and tagafur, or paclitaxel, and car-
boplatin, were tested as radiosensitizers, but cisplatin
remains the most effective agent in treating cervical
cancer11.
Trend 3: Sentinel Lymph Node-Mapping
Sentinel lymph node mapping is well developed for the
surgery of breast cancer, for the reduction of morbidity
after total axillary lymph node dissection. Similarly, this
procedure is currently applied during radical surgery 
of cervical cancer to reduce the lower-extremity lym-
phedema, lymphagitis or pelvic lymphocyst after pelvic
lymph node dissection and is often coupled with post-
operative pelvic radiotherapy. Metastable technetium-
99 (Tc-99m) lymphoscintigraphy and blue dye injection
are used to investigate the sentinel lymph node distribu-
tion during pelvic node dissection. A recent study by
Wydra et al.12 reported the sensitivity (86.4%), negative
predictive value (95.5%), and specificity (100%) using a
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combination of these two methods in 100 patients
with early cervical cancer.
Trend 4: Consolidation Chemotherapy After
CCRT in Locally Advanced Cervical Cancer
CCRT is the standard treatment in locally advanced
cervical cancer. Although CCRT improves the survival rate
by 30–50%, the 5-year survival rate in these patients
remains < 65%. Local failure and distant metastases
often happen after treatment. The concept of post-
radiotherapy consolidation chemotherapy originates
from maintenance chemotherapy of advanced ovar-
ian cancer, which can either suppress the microscopic
circulating cancer cells in the systemic circulation or
achieve the anti-angiogenesis effects (metronomic
therapy) by maintaining the blood concentration of
the chemotherapeutic agent. Vrdoljak et al.13 reported
a clinical trial in which locally advanced cervical cancer
patients who received external beam pelvic radiation
therapy without chemotherapeutic agent concurrently.
A combination of ifosfamide (2 g/m2) and cisplatin (75
mg/m2) was used concurrently during two low-dose rate
brachytherapy applications. After completing concomi-
tant chemoradiation therapy, four courses of systemic
chemotherapy with the same two-drug regimen were
given as consolidation therapy. The results showed a high
response rate (nearly 100%) and high recurrence-free
rate (88.7%) during a follow-up of 49 months. The trial
also demonstrated acceptable morbidity rate (25%
grade 3, 11% grade 4 hematologic toxicities). Only 16%
of the patients developed delayed major complications.
This protocol may become more promising than the
traditional CCRT schedule.
Trend 5: Neoadjuvant Chemotherapy 
(NACT)
NACT plus surgery have demonstrated itself on phase
II trials to be feasible as a valid replacement for con-
ventional radiotherapy or surgery14–16. However, most
phase III trials of NACT plus radiotherapy have failed to
show further benefit than those of radiotherapy alone17.
In contrast, a recent meta-analysis by Medical Research
Council (UK)18 showed the benefit of a more intensive
chemotherapy at shorter cycle length or higher dose
intensity for the NACT plus radiotherapy treatment.
This meta-analysis included 2,074 patients from 18
different trials with a median follow-up analysis of 5.7
years. Sardi et al.19, in a recent review article, drew
attention to the significance of this meta-analysis and
highlighted the potential application of NACT plus
radiotherapy as part of a new therapeutic trend in treat-
ing locally advanced cervical cancer patients. Further
research is required to verify and conclude this finding.
Trend 6: Improvement of Systemic
Chemotherapy
Single-agent cisplatin (50 mg/m2) administered every 3
weeks apart has been the standard systemic chemother-
apeutic agent for the treatment of advanced/recurrent
and metastatic SCC of the uterine cervix. It demon-
strated a 50% objective response rate in previously
untreated patients20. Several new single agents with
antineoplastic activity were trialed in combination with
cisplatin, including ifosfamide21, oxaliplatin, paclitaxel22,
and gemcitabine23. Ifosfamide plus cisplatin demon-
strated a significant improvement in response rate and
progressive-free survival but failed to improve the overall
survival24. The combination of ifosfamide and cisplatin
showed limited improvement on the progressive-free
survival (1.4 months). A recent Gynecologic Oncology
Group (GOG)-169 study25 demonstrated that a combi-
nation of paclitaxel and cisplatin also showed limited
improvement in progressive-free survival without any
improvement in overall survival. The abovementioned
trials once again reinforce the role of single-agent cis-
platin as the current standard systemic therapy for cer-
vical cancer. There have been two new trends in multiple
chemotherapeutic agent combinations recently, the
first is the combination of methotrexate, vinblastine,
doxorubicin, and cisplatin (MVAC)26, and the other is
cisplatin plus topotecan (GOG-179)27. The three-arm
clinical trial involving the MVAC regimen was forced to
close prematurely because of many treatment-related
deaths. In the comparison between cisplatin plus
topotecan and single-agent cisplatin, the combination
group showed a statistically significant improvement in
response rate (27% vs. 13%), progressive-free survival (4.6
months vs. 2.9 months) and overall survival (9.4 months
vs. 6.5 months). The combination of cisplatin plus
topotecan has now replaced the single-agent cisplatin to
become the most effective systemic chemotherapeutic
combination agents.
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Trend 7: Prophylactic and Therapeutic
Vaccines
Oncogenic HPV are epitheliotropic and detectable in over
99% of cervical cancers. The vaccines of HPV are classi-
fied into two major groups: prophylactic and thera-
peutic vaccines. The prophylactic vaccine protects against
HPV infection, and the therapeutic vaccine kills previ-
ously infected or transformed keratinocytes. Prophylactic
vaccines can induce a high titer of blood antibodies
against oncogenic HPV 16 and 18. They can retard the
progression of cervical cancer or prevent the cancer
from occurring. Two types of prophylactic vaccines are
recently under investigation. However, the quadrivalent
vaccine (Gardasil) has already been approved for market-
ing, while the bi-valent HPV vaccine (Cervarix) is still
pending approval. On the other hand, therapeutic vac-
cines are currently being developed in order to
increase anti-HPV natural CD4+ and CD8+ T-cell immu-
nity in women infected during their sexual activity.
Researchers have designed these vaccines to target the
activity of the E6 and E7 oncoproteins28. These therapeu-
tic vaccines can be divided to several subgroups29, such
as viral-vector, bacterial-vector, peptide, protein, DNA,
dendrite cell-based, and tumor cell-based. A number of
approaches have shown significant therapeutic benefit in
preclinical papillomavirus models16. Although the ther-
apeutic vaccines might have efficiency similar to surgi-
cal treatment of CIN30, the current therapeutic vaccine
trials are still less mature with respect to disease clear-
ance. Further testing in patient populations is required
to determine the most effective curative strategy.
Trend 8: Molecular/target Drugs
Advances in molecular biology have led to the discovery
of a number of cancer pathways. Having gained sub-
stantial understanding of the mechanisms of cell pro-
liferation, cell cycle regulation, apoptosis, angiogenesis
and inflammation, pharmaceutical companies have
developed several kinds of molecular or protein drugs
to target the key enzymes, growth factors or receptors in
order to block these pathways. For example, erlotinib
(OSI-774) is an endothelial growth factor receptor tyro-
sine kinase inhibitor, which has been used to treat cer-
vical cancer31. Although only limited drugs are clinically
useful in the treatment of breast cancer, lung cancer
or other solid tumors, many newly developed drugs
are now undergoing further experiments. Target ther-
apy can play either a major or an assistant role in the
future treatments of cancers, including cervical cancer
and other gynecologic malignancies.
Conclusion
This review summarizes the current trends in the man-
agement of cervical cancer. Although the results of
some clinical trials are still inconclusive, many clinical
improvements have been observed in recent years. It
is the author’s belief that the investigation of alternate
treatment modalities that are more conservative, less
toxic, less harmful, and more effective is an ongoing
objective in the field of gynecologic oncology.
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